CA2426405A1 - Variants alpha du recepteur d'oestrogene et techniques de detection de ces variants - Google Patents
Variants alpha du recepteur d'oestrogene et techniques de detection de ces variants Download PDFInfo
- Publication number
- CA2426405A1 CA2426405A1 CA002426405A CA2426405A CA2426405A1 CA 2426405 A1 CA2426405 A1 CA 2426405A1 CA 002426405 A CA002426405 A CA 002426405A CA 2426405 A CA2426405 A CA 2426405A CA 2426405 A1 CA2426405 A1 CA 2426405A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- estrogen receptor
- protein
- sequence
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- High Energy & Nuclear Physics (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention se fonde sur le séquençage génomique d'ADN du chromosome 6 et sur les ADNc de façon à définir la structure génomique des gènes alpha du récepteur d'oestrogène (ESR) et de nouveaux polymorphismes/haplotypes dans la protéine et/ou le gène du récepteur d'oestrogène. Ces polymorphismes/haplotypes peuvent conduire à divers troubles qui sont modulés/induits par un récepteur d'oestrogène variant, tels qu'une sensibilité pour le cancer, l'ostéoporose, les pathologies cardio-vasculaires, etc.. Fondée sur cette technique de séquençage, la présente invention concerne des séquences nucléotidiques génomiques, des séquences d'ADNc, des séquences d'acides aminés et des polymorphismes/haplotypes de séquence dans les gènes alpha ESR, des techniques de détection de ces séquences/polymorphismes/haplotypes dans un échantillon, des techniques de détermination d'un risque de développer une pathologie induite par un récepteur d'oestrogène variant ou d'en être déjà atteint, et des technique de criblage de composés utilisés pour traiter les pathologies induites par un récepteur d'oestrogène variant.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69241400A | 2000-10-20 | 2000-10-20 | |
| US09/692,414 | 2000-10-20 | ||
| US76818401A | 2001-01-24 | 2001-01-24 | |
| US09/768,184 | 2001-01-24 | ||
| US80407601A | 2001-03-13 | 2001-03-13 | |
| US09/804,076 | 2001-03-13 | ||
| US82631401A | 2001-04-05 | 2001-04-05 | |
| US09/826,314 | 2001-04-05 | ||
| PCT/US2001/025990 WO2002034945A2 (fr) | 2000-10-20 | 2001-08-21 | Variants alpha du recepteur d'oestrogene et techniques de detection de ces variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2426405A1 true CA2426405A1 (fr) | 2002-05-02 |
Family
ID=27505440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002426405A Abandoned CA2426405A1 (fr) | 2000-10-20 | 2001-08-21 | Variants alpha du recepteur d'oestrogene et techniques de detection de ces variants |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1328661A2 (fr) |
| JP (1) | JP2004531228A (fr) |
| AU (1) | AU2001286560A1 (fr) |
| CA (1) | CA2426405A1 (fr) |
| WO (1) | WO2002034945A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020123095A1 (en) * | 1999-10-20 | 2002-09-05 | Pe Corporation (Ny) | Estrogen receptor alpha variants and methods of detection thereof |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| ES2970246T3 (es) | 2015-03-27 | 2024-05-27 | Immatics Biotechnologies Gmbh | Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores |
-
2001
- 2001-08-21 JP JP2002560443A patent/JP2004531228A/ja active Pending
- 2001-08-21 WO PCT/US2001/025990 patent/WO2002034945A2/fr not_active Application Discontinuation
- 2001-08-21 AU AU2001286560A patent/AU2001286560A1/en not_active Abandoned
- 2001-08-21 CA CA002426405A patent/CA2426405A1/fr not_active Abandoned
- 2001-08-21 EP EP01966016A patent/EP1328661A2/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002034945A3 (fr) | 2002-08-08 |
| EP1328661A2 (fr) | 2003-07-23 |
| WO2002034945A2 (fr) | 2002-05-02 |
| AU2001286560A1 (en) | 2002-05-06 |
| JP2004531228A (ja) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017267184B2 (en) | Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy | |
| KR102291355B1 (ko) | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 | |
| US20230056182A1 (en) | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear | |
| CN107223159A (zh) | 源自特定细胞类型的dna的检测及相关方法 | |
| AU2016364667A1 (en) | Materials and methods for treatment of Alpha-1 antitrypsin deficiency | |
| AU2016351889A1 (en) | Detection of foetal chromosomal aneuploidies using DNA regions that are differentially methylated between the foetus and the pregnant female | |
| WO1998045436A2 (fr) | Marqueurs secretes de sequence exprimee (sest) | |
| CA2936612A1 (fr) | Polymorphismes atf6 associes a une infarctus du myocarde, methode de detection et utilisations associees | |
| WO1998045437A2 (fr) | MARQUEURS SECRETES DE SEQUENCE EXPRIMEE (sEST) | |
| KR20210027384A (ko) | Scn9a 발현을 조절하기 위한 올리고뉴클레오티드 | |
| KR20220012230A (ko) | 스플라이싱 및 번역을 조절하기 위한 방법 및 조성물 | |
| KR20160037895A (ko) | 성장 호르몬 수용체의 조절인자 | |
| KR20220025749A (ko) | 대장암의 검출 | |
| KR20220024184A (ko) | 대장암의 검출 | |
| KR20100128298A (ko) | 카텝신 ｃ의 용도 | |
| WO2006022629A1 (fr) | Procédés d’identification de risque de diabète de type ii et leurs traitements | |
| CA2458202A1 (fr) | Variantes alpha du recepteur d'oestrogenes et methodes de detection associees | |
| CN101151371A (zh) | 治疗中的逆转录转座子抑制 | |
| CN111344408A (zh) | 用于调控fndc3b表达的寡核苷酸 | |
| CA2400915A1 (fr) | Variants de recepteurs oestrogeniques alpha et procede de detection desdits variants | |
| WO2006022636A1 (fr) | Méthodes d’identification du risque d’apparition de diabètes de type ii et traitements associés | |
| CA2474759A1 (fr) | Gene pour le traitement d'une la maladie occlusive arterielle peripherique | |
| US6818758B2 (en) | Estrogen receptor beta variants and methods of detection thereof | |
| CA2426405A1 (fr) | Variants alpha du recepteur d'oestrogene et techniques de detection de ces variants | |
| KR20230005933A (ko) | Atxn1을 조정하는 화합물 및 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |